期刊文献+

外源性CSMD1对黑色素瘤A375细胞活性的影响

Effects of exogenous CSMD1 on activity of A375 melanoma cells
原文传递
导出
摘要 目的 研究经pCDNA-3.0-CSMD1转染的A375细胞的活性,探讨外源性CSMD1的表达对黑色素瘤细胞活性的影响.方法 培养人黑色素瘤A375细胞株,利用前期实验获得的CSMD1基因,构建质粒、转染细胞.A375细胞分为:A组,未转染的A375细胞;B组,经pCDNA-3.0转染的A375细胞;C组,经pCDNA-3.0-CSMD1转染的A375细胞.应用MTT法、细胞周期分析法、细胞凋亡相关检测(DAPI染色、Annexin V-FITC/PI双染、Transwell细胞迁移实验)等方法,检测A375细胞的活性,并进行统计学分析.结果 C组细胞的增殖率明显低于其他两组细胞(P<0.05);C组细胞G1期的比例高于其他两组细胞(P<0.05);仅在C组细胞中发现凋亡细胞核固缩,并在48 h内出现核碎裂;C组细胞凋亡率为32.7%,明显高于A组(6.6%)和B组(8.4%)细胞(P<0.05);与A组和B组细胞相比,C组细胞极少迁移至聚碳酸酯膜下层(P<0.05).结论 外源性CSMD1可以抑制黑色素瘤A375细胞的活性,这有可能为黑色素瘤的治疗提供一种新的途径. Objective To study the activity of pCDNA-3.0-CSMD1 transfected A375 cells,and investigate effects of exogenous CSMD1 on activity of A375 melanoma cells.Methods The cultured A375 melanoma cells and CSMD1 gene which obtained by prevenient experiments were used to construct the plasmid and transfected A375 cells.The A375 cells were divided into the A group (the cells without transfection),the B group (the cells transfected with pCDNA-3.0) and the C group (the cells transfected with pCDNA-3.0 and CSMD1).The activity of A375 cells was detected with MTT assay,cell cycle analysis,measurement of apoptotic cell death (DAPI staining assty,Annexin-V FITC/PI double staining assay,Transwell migration assay)and the statistical analysis aws also performed.Results The rate of cell proliferation in the C group was lower than those in the other groups (P< 0.05),and its proportion of G1 phase was higher (P< 0.05).Apoptotic nuclear condensation with nuclear fragmentation was only observed in the C group within 48 hours.The percentage of apoptosis in the C group was 32.7 %,which was significantly higher compared to Group A (6.6 %) and Group B (8.4%),P<0.05.The cells in the C group significantly less migrated to the lower membrane compared to cells in the A and B groups (P < 0.05).Conclusion Exogenous CSDM1 can inhibit activity of melanoma A375 cells,and may provide a novel target for clinical treatment.
出处 《中国美容整形外科杂志》 CAS 2014年第10期638-640,共3页 Chinese Journal of Aesthetic and Plastic Surgery
关键词 CSMD1 黑色素瘤 A375细胞 CSMD1 Melanoma A375 cell
  • 相关文献

参考文献10

  • 1Farrell LC,Crimm H,Meeh P,et al.Somatic mutations to CSMD1 in colorectal adenocarcinomas[J].Cancer Biol Ther,2008,7(4):609-613.
  • 2Wright K,Wilson PJ,Kerr J,et al.Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas[J].Oncogene,1998,17(9):1185-1188.
  • 3Kerbel RS.A cancer therapy resistant to resistance[J].Nature,1997,390(6658):335-336.
  • 4唐明睿,王玉新,郭澍,孙强,王迪.CSMD1在黑色素瘤A375细胞中的表达及意义[J].中国美容整形外科杂志,2013,24(4):253-255. 被引量:1
  • 5王亚丽(综述),吴瑾(审校).恶性黑色素瘤诊断与治疗进展[J].中国综合临床,2012,28(11):1226-1228. 被引量:6
  • 6Garbe C,Peris K,Hauschild A,et al.Diagnosis and treatment of melanoma.European consensus-based interdisciplinay guideline Update2012[J].Eur J Cancer,2010,48(15):2375-2390.
  • 7Ma C,Quesnelle KM,Sparano A,et al.Characterization CSMD1 in a large set of primary lung,head and neck,breast and skin cancer tissues[J].Cancer Biol Ther,2009,8(10):907-916.
  • 8Henshall SM,Afar DE,Hiller J,et al.Survival analysis of genomewide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse[J].Cancer Res,2003,63(14):196.
  • 9Kamal M,Shaaban AM,Zhang L,et al.Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma[J].Breast Cancer Res Treat,2010,121(3):555-563.
  • 10Midorikawa Y,Yamamoto S,Tsuji S,et al.Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis[J].Hepatology,2009,49(2):513-522.

二级参考文献37

  • 1周际昌,主编.实用肿瘤内科学[M].北京:人民卫生出版社,2010:774-777.
  • 2Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and futUre prospects [J]. Oncologist,2011,16( 1 ) :5-24.
  • 3Corrie PG, Basu B, Zaki KA. Targeting angiogenesis in melanoma: prospects for the future [ J ]. Ther Adv Med Oncol, 2010,2 ( 6 ) : 367-380.
  • 4Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase Ⅲ study of 1 month versus 1 year of adjuvant high-dose interferon alfa- 2b in patients with resected high-risk melanoma [ J ]. J Clin Oncol, 2009,27(6) :939-944.
  • 5Egberts F, Kahler KC, Livingstone E, et al. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results [ J]. Onkologie, 2008,31 ( 7 ) : 398 -403.
  • 6Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma [J]. Clin Cancer Res,2009,15 (10) :3495-3502.
  • 7Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma [J]. Clin Cancer Res, 2008,14 (23) : 7726-7732.
  • 8Guo J, Si L, Kong Y, et al. Phase Ⅱ, open-label, single-arm trim of imatinib mesylate in patients with metastatic melanoma harboring c- Kit mutation or amplification [ J ]. J Clin Oncol, 2011,29 ( 21 ) : 2904 -2909.
  • 9Si L,Kong Y,Xu X,et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort [ J ]. Eur J Cancer,2012,48( 1 ) :94-100.
  • 10Ma C, QuesneUe KM, Sparano A, et a1. Characterization CSMDI in a large set of primary lung, head and neck, breast and skin cancer tissues[J]. Cancer Bioi Ther, 2009,8 ( 10) :907 -916.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部